A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB019 in Healthy Subjects and Psoriasis Patients.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB019 in Healthy Subjects and Psoriasis Patients.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs ANB 019 (Primary) ; ANB 019 (Primary)
  • Indications Generalised pustular psoriasis; Palmoplantar pustulosis; Plaque psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors AnaptysBio
  • Most Recent Events

    • 06 Nov 2017 According to an AnaptysBio media release, detailed data is anticipated to be presented at a future medical conference.
    • 06 Nov 2017 According to an AnaptysBio media release, This interim analysis was conducted after the 85-day, post-dosing monitoring period has been completed for the single ascending dose cohorts while monitoring is on-going for the multiple ascending dose cohorts.
    • 06 Nov 2017 Interim analysis presenteded in an AnaptysBio Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top